We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE’s share was trading at $103.80 as of March 4th.

In recent months, BioNTech has moved further beyond its COVID-19 roots by acquiring Chinese startup Biotheseus and inking a major Bristol Myers partnership around oncology candidate BNT327, which ...

BioNTech SE (NASDAQ:BNTX) is one of the best stocks to buy and hold for the next 6 months. On February 2, research firm Leerink Partners downgraded BioNTech SE (NASDAQ:BNTX) to a Market Perform from ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...

BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. Click to read why BNTX is a Buy.

High-rolling investors have positioned themselves bullish on BioNTech (NASDAQ:BNTX), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...

BioNTech share performance snapshot BioNTech (NasdaqGS:BNTX) has seen mixed share price moves recently, with a small 1 day decline, a gain over the past week, a loss over the past month, and a ...

BioNTech SE (NASDAQ:BNTX) is one of the Stocks That Will Go To The Moon in 2026. On December 18, BioNTech SE (NASDAQ:BNTX) announced the closing of its acquisition of CureVac N.V. (NASDAQ:CVAC), which ...

BioNTech SE Sponsored ADR (BNTX) shares rallied 11.8% in the last trading session to close at $118. This move can be attributable to notable volume with a higher number of shares being traded than in ...